A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder

Eric Hollander, Stacey Wasserman, Erika N. Swanson, William Chaplin, Melissa L. Schapiro, Karen Zagursky, Sherie Novotny

Research output: Contribution to journalArticle

121 Citations (Scopus)

Abstract

Atypical antipsychotics have been shown to improve disruptive and repetitive behaviors in pervasive developmental disorders (PDDs), but they require assessment of potential side effects. This is the first placebo-controlled trial of olanzapine in the treatment of children and adolescents with PDD. Eleven patients with a diagnosis of either autism, Asperger's syndrome, or PDD not otherwise specified (PDD-NOS) and aged 6-14 years were randomised into an 8-week double-blind, placebo-controlled, parallel treatment study with olanzapine. There was a significant linear trend x group interaction on the Clinical Global Impressions-Improvement (CGI-I) and 50% on olanzapine versus 20% on placebo were responders. Olanzapine was associated with significant weight gain (7.5 ± 4.8 lbs vs. 1.5 ± 1.5 lbs on placebo). Olanzapine may be a promising treatment for improving global functioning of PDDs, but the risk of significant weight gain remains a concern. Additional studies are needed to determine the efficacy and safety of olanzapine in the treatment of children with PDD.

Original languageEnglish (US)
Pages (from-to)541-548
Number of pages8
JournalJournal of Child and Adolescent Psychopharmacology
Volume16
Issue number5
DOIs
StatePublished - Oct 2006
Externally publishedYes

Fingerprint

olanzapine
Placebos
Weight Gain
Asperger Syndrome
Therapeutics
Autistic Disorder
Antipsychotic Agents
Safety

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Psychiatry and Mental health
  • Pediatrics, Perinatology, and Child Health
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder. / Hollander, Eric; Wasserman, Stacey; Swanson, Erika N.; Chaplin, William; Schapiro, Melissa L.; Zagursky, Karen; Novotny, Sherie.

In: Journal of Child and Adolescent Psychopharmacology, Vol. 16, No. 5, 10.2006, p. 541-548.

Research output: Contribution to journalArticle

Hollander, Eric ; Wasserman, Stacey ; Swanson, Erika N. ; Chaplin, William ; Schapiro, Melissa L. ; Zagursky, Karen ; Novotny, Sherie. / A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder. In: Journal of Child and Adolescent Psychopharmacology. 2006 ; Vol. 16, No. 5. pp. 541-548.
@article{a324c122576e4498be2bb6108091b4b3,
title = "A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder",
abstract = "Atypical antipsychotics have been shown to improve disruptive and repetitive behaviors in pervasive developmental disorders (PDDs), but they require assessment of potential side effects. This is the first placebo-controlled trial of olanzapine in the treatment of children and adolescents with PDD. Eleven patients with a diagnosis of either autism, Asperger's syndrome, or PDD not otherwise specified (PDD-NOS) and aged 6-14 years were randomised into an 8-week double-blind, placebo-controlled, parallel treatment study with olanzapine. There was a significant linear trend x group interaction on the Clinical Global Impressions-Improvement (CGI-I) and 50{\%} on olanzapine versus 20{\%} on placebo were responders. Olanzapine was associated with significant weight gain (7.5 ± 4.8 lbs vs. 1.5 ± 1.5 lbs on placebo). Olanzapine may be a promising treatment for improving global functioning of PDDs, but the risk of significant weight gain remains a concern. Additional studies are needed to determine the efficacy and safety of olanzapine in the treatment of children with PDD.",
author = "Eric Hollander and Stacey Wasserman and Swanson, {Erika N.} and William Chaplin and Schapiro, {Melissa L.} and Karen Zagursky and Sherie Novotny",
year = "2006",
month = "10",
doi = "10.1089/cap.2006.16.541",
language = "English (US)",
volume = "16",
pages = "541--548",
journal = "Journal of Child and Adolescent Psychopharmacology",
issn = "1044-5463",
publisher = "Mary Ann Liebert Inc.",
number = "5",

}

TY - JOUR

T1 - A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder

AU - Hollander, Eric

AU - Wasserman, Stacey

AU - Swanson, Erika N.

AU - Chaplin, William

AU - Schapiro, Melissa L.

AU - Zagursky, Karen

AU - Novotny, Sherie

PY - 2006/10

Y1 - 2006/10

N2 - Atypical antipsychotics have been shown to improve disruptive and repetitive behaviors in pervasive developmental disorders (PDDs), but they require assessment of potential side effects. This is the first placebo-controlled trial of olanzapine in the treatment of children and adolescents with PDD. Eleven patients with a diagnosis of either autism, Asperger's syndrome, or PDD not otherwise specified (PDD-NOS) and aged 6-14 years were randomised into an 8-week double-blind, placebo-controlled, parallel treatment study with olanzapine. There was a significant linear trend x group interaction on the Clinical Global Impressions-Improvement (CGI-I) and 50% on olanzapine versus 20% on placebo were responders. Olanzapine was associated with significant weight gain (7.5 ± 4.8 lbs vs. 1.5 ± 1.5 lbs on placebo). Olanzapine may be a promising treatment for improving global functioning of PDDs, but the risk of significant weight gain remains a concern. Additional studies are needed to determine the efficacy and safety of olanzapine in the treatment of children with PDD.

AB - Atypical antipsychotics have been shown to improve disruptive and repetitive behaviors in pervasive developmental disorders (PDDs), but they require assessment of potential side effects. This is the first placebo-controlled trial of olanzapine in the treatment of children and adolescents with PDD. Eleven patients with a diagnosis of either autism, Asperger's syndrome, or PDD not otherwise specified (PDD-NOS) and aged 6-14 years were randomised into an 8-week double-blind, placebo-controlled, parallel treatment study with olanzapine. There was a significant linear trend x group interaction on the Clinical Global Impressions-Improvement (CGI-I) and 50% on olanzapine versus 20% on placebo were responders. Olanzapine was associated with significant weight gain (7.5 ± 4.8 lbs vs. 1.5 ± 1.5 lbs on placebo). Olanzapine may be a promising treatment for improving global functioning of PDDs, but the risk of significant weight gain remains a concern. Additional studies are needed to determine the efficacy and safety of olanzapine in the treatment of children with PDD.

UR - http://www.scopus.com/inward/record.url?scp=33750952522&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750952522&partnerID=8YFLogxK

U2 - 10.1089/cap.2006.16.541

DO - 10.1089/cap.2006.16.541

M3 - Article

C2 - 17069543

AN - SCOPUS:33750952522

VL - 16

SP - 541

EP - 548

JO - Journal of Child and Adolescent Psychopharmacology

JF - Journal of Child and Adolescent Psychopharmacology

SN - 1044-5463

IS - 5

ER -